HC Wainwright Has Negative Estimate for CATX FY2025 Earnings

Perspective Therapeutics, Inc. (NYSE:CATX) – HC Wainwright lowered their FY2025 EPS estimates for shares of Perspective Therapeutics in a research note issued on Wednesday, March 19th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings of ($1.20) per share for the year, down from their prior estimate of ($1.19). HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($0.88) per share.

A number of other equities research analysts have also weighed in on CATX. Scotiabank started coverage on shares of Perspective Therapeutics in a research note on Friday, March 7th. They set a “sector outperform” rating and a $15.00 target price for the company. Wedbush reissued an “outperform” rating and set a $11.00 price objective on shares of Perspective Therapeutics in a research report on Monday, March 17th. Cantor Fitzgerald raised shares of Perspective Therapeutics to a “strong-buy” rating in a research report on Tuesday, March 4th. Bank of America downgraded shares of Perspective Therapeutics from a “buy” rating to a “neutral” rating and cut their price objective for the company from $24.00 to $5.00 in a research report on Monday, November 25th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $16.00 price objective on shares of Perspective Therapeutics in a research report on Tuesday, January 14th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Perspective Therapeutics presently has an average rating of “Buy” and an average target price of $14.56.

Perspective Therapeutics Trading Up 1.2 %

Shares of CATX opened at $2.52 on Friday. The firm has a fifty day simple moving average of $3.03 and a two-hundred day simple moving average of $6.81. Perspective Therapeutics has a 1-year low of $2.32 and a 1-year high of $19.05.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of CATX. Victory Capital Management Inc. boosted its holdings in Perspective Therapeutics by 328.7% in the 3rd quarter. Victory Capital Management Inc. now owns 50,460 shares of the company’s stock worth $674,000 after buying an additional 38,690 shares during the period. CIBC Asset Management Inc bought a new position in Perspective Therapeutics in the 3rd quarter worth $259,000. Intech Investment Management LLC bought a new position in Perspective Therapeutics in the 3rd quarter worth $137,000. Charles Schwab Investment Management Inc. boosted its holdings in shares of Perspective Therapeutics by 221.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 433,522 shares of the company’s stock valued at $5,788,000 after purchasing an additional 298,778 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its holdings in shares of Perspective Therapeutics by 8.9% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 20,514 shares of the company’s stock valued at $274,000 after purchasing an additional 1,672 shares during the last quarter. Institutional investors own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.